About autolus therapeutics - AUTL
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
AUTL At a Glance
Autolus Therapeutics Plc
The Mediaworks
London, Greater London W12 7FP
| Phone | 44-20-3829-6230 | Revenue | 75.56M | |
| Industry | Pharmaceuticals: Major | Net Income | -288,199,915.75 | |
| Sector | Health Technology | 2025 Sales Growth | 646.367% | |
| Fiscal Year-end | 12 / 2026 | Employees | 752 | |
| View SEC Filings |
AUTL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.009 |
| Price to Book Ratio | 3.967 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.132 |
| Enterprise Value to Sales | 7.662 |
| Total Debt to Enterprise Value | 0.607 |
AUTL Efficiency
| Revenue/Employee | 100,484.271 |
| Income Per Employee | -383,244.569 |
| Receivables Turnover | 1.004 |
| Total Asset Turnover | 0.11 |
AUTL Liquidity
| Current Ratio | 5.889 |
| Quick Ratio | 5.437 |
| Cash Ratio | 4.115 |
AUTL Profitability
| Gross Margin | -27.831 |
| Operating Margin | -372.448 |
| Pretax Margin | -392.842 |
| Net Margin | -381.398 |
| Return on Assets | -42.018 |
| Return on Equity | -95.201 |
| Return on Total Capital | -54.406 |
| Return on Invested Capital | -46.608 |
AUTL Capital Structure
| Total Debt to Total Equity | 197.378 |
| Total Debt to Total Capital | 66.373 |
| Total Debt to Total Assets | 59.685 |
| Long-Term Debt to Equity | 189.201 |
| Long-Term Debt to Total Capital | 63.623 |
Autolus Therapeutics in the News
Blackstone to invest up to $250 million in Autolus Therapeutics of U.K.
Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said.